Straits Times Index
3,293.14 +0.45 (+0.01%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,207.13 +444.10 (+2.50%) FTSE 100
8,152.55 +31.31 (+0.39%) Bitcoin USD
57,810.70 +1,020.97 (+1.80%) CMC Crypto 200
1,268.92 -1.82 (-0.14%)
Adagene Inc. (ADAG)
| Previous close | 2.2500 |
| Open | 2.2400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2400 - 2.5800 |
| 52-week range | 1.1000 - 4.3800 |
| Volume | |
| Avg. volume | 23,252 |
| Market cap | 102.886M |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings date | 28 Mar 2024 - 02 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
GlobeNewswireAdagene Reports Full Year 2023 Financial Results and Provides Corporate Update
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 - - Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 -
- GlobeNewswire
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Lenz is the Associate Director for Clinica
- GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody® ADG126, including key milest
